Equity Profile

AZN

AstraZeneca PLC

Health CarePharmaceuticals$244.0B

Feb10Tue

Pre-Earnings Brief

UpcomingQ1-2018Pre-Market9:00 AM EST

Company Snapshot

AstraZeneca PLC (AZN) is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Operating in the health care sector, AstraZeneca plays a crucial role in addressing major health challenges, including cancer, cardiovascular diseases, and respiratory conditions.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

AZN Q1-2018 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+72.85%

Avg Stock Reaction

-1.24%

Last Quarter Recap

In the last quarter, AstraZeneca reported an EPS of $1.30, significantly exceeding expectations by 66.36%. The stock reacted positively, gaining 2.16% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, Wall Street is cautiously optimistic about AstraZeneca's upcoming earnings report, especially given its strong performance in the last quarter.

Bull Case

If AstraZeneca continues to beat EPS estimates, it could signal robust demand for its products and lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations, it may raise concerns about its growth trajectory and impact investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for this quarter?

Given AstraZeneca's recent strong performance, the EPS figure will be crucial in determining if the company can maintain its growth momentum.

How is revenue growth trending in key therapeutic areas?

Understanding revenue trends in critical segments will provide insight into the company's market position and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate AstraZeneca's ability to maintain its growth trajectory, particularly in light of recent product launches and market expansions.

Supporting Evidence

AstraZeneca's recent EPS surprises indicate strong underlying demand for its products.

The options market is pricing in a 4.3% move, suggesting that traders expect significant volatility, which may not align with the company's growth potential.

Key Risk

If AstraZeneca's revenue growth outpaces expectations, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on AstraZeneca's ability to sustain its recent earnings momentum and revenue growth.

Bull Confirmed If

AstraZeneca reports an EPS exceeding $1.30, indicating continued strong performance.

Bear Confirmed If

An EPS below $1.00 would raise concerns about the company's growth and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±4.3%

Historical Avg

±4.2%

In line with history

The options market is pricing in a potential move of approximately 4.3% in either direction following the earnings report.

Options are pricing ±4.3% while AZN has averaged ±4.2% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.3%

30d HV

20.7%

Calls (35K)P/C Ratio: 1.14Puts (91K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If AstraZeneca beats expectations, history suggests a potential stock increase of around 1.01%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary from management.

Miss

A miss could lead to a decline of approximately 1.06%, reflecting investor disappointment and concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their market performance.
2Insights into revenue growth in key therapeutic areas such as oncology and cardiovascular.
3Management's outlook on market conditions and competitive landscape.
4Details on cost management and operational efficiencies.
5Guidance on future earnings expectations and strategic initiatives.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

ORIX Corporation

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

AZN Q1-2018 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+72.85%

Avg Stock Reaction

-1.24%

Last Quarter Recap

In the last quarter, AstraZeneca reported an EPS of $1.30, significantly exceeding expectations by 66.36%. The stock reacted positively, gaining 2.16% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, Wall Street is cautiously optimistic about AstraZeneca's upcoming earnings report, especially given its strong performance in the last quarter.

Bull Case

If AstraZeneca continues to beat EPS estimates, it could signal robust demand for its products and lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations, it may raise concerns about its growth trajectory and impact investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for this quarter?

Given AstraZeneca's recent strong performance, the EPS figure will be crucial in determining if the company can maintain its growth momentum.

How is revenue growth trending in key therapeutic areas?

Understanding revenue trends in critical segments will provide insight into the company's market position and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate AstraZeneca's ability to maintain its growth trajectory, particularly in light of recent product launches and market expansions.

Supporting Evidence

AstraZeneca's recent EPS surprises indicate strong underlying demand for its products.

The options market is pricing in a 4.3% move, suggesting that traders expect significant volatility, which may not align with the company's growth potential.

Key Risk

If AstraZeneca's revenue growth outpaces expectations, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on AstraZeneca's ability to sustain its recent earnings momentum and revenue growth.

Bull Confirmed If

AstraZeneca reports an EPS exceeding $1.30, indicating continued strong performance.

Bear Confirmed If

An EPS below $1.00 would raise concerns about the company's growth and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±4.3%

Historical Avg

±4.2%

In line with history

The options market is pricing in a potential move of approximately 4.3% in either direction following the earnings report.

Options are pricing ±4.3% while AZN has averaged ±4.2% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.3%

30d HV

20.7%

Calls (35K)P/C Ratio: 1.14Puts (91K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If AstraZeneca beats expectations, history suggests a potential stock increase of around 1.01%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary from management.

Miss

A miss could lead to a decline of approximately 1.06%, reflecting investor disappointment and concerns about future growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their market performance.
2Insights into revenue growth in key therapeutic areas such as oncology and cardiovascular.
3Management's outlook on market conditions and competitive landscape.
4Details on cost management and operational efficiencies.
5Guidance on future earnings expectations and strategic initiatives.